What is BPC-157? A plain-English explainer

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide originally isolated from a protein in human gastric juice. It has been studied extensively in rodents for tendon, ligament, gut and brain repair, and the animal results are often positive^[1]. Controlled human data, however, is essentially absent. BPC-157 is not approved as a medicine by the FDA, the EMA, the MHRA, or any national agency in our coverage area, and it sits on the WADA Prohibited List under S0 (non-approved substances)^[2].

What the animal research shows

The preclinical literature is genuinely interesting. Rat studies report accelerated healing of transected Achilles tendons, medial-collateral-ligament injuries, segmental muscle defects and traumatic brain injuries. Rodent models of ulcerative colitis and gastric ulcer also show reduced lesion size with BPC-157 administration. A 2021 review in Frontiers in Pharmacology, authored by Seiwerth and colleagues across 26 co-authors, catalogued these wound-healing findings across skin, tendon, ligament, muscle, bone and nerve tissue^[1]. The proposed mechanism involves angiogenesis (the growth of new blood vessels into damaged tissue), modulation of growth-factor pathways including VEGF and basic FGF, and influence on the nitric-oxide system.

Most of this work comes from a small number of research groups, centred on the University of Zagreb team led by Predrag Sikiric, who first characterised the peptide in 1991. That concentration of authorship is worth noting: it means the positive findings have not been widely replicated by independent labs. The typical study design uses intraperitoneal or intragastric administration in rats at doses ranging from 10 micrograms per kilogram to roughly 1 milligram per kilogram, with wide variation between research groups.

Why the human evidence gap matters

There is no published phase-2 or phase-3 randomised controlled trial of BPC-157 for any indication. The doses quoted online (commonly 200 to 500 micrograms once or twice daily by subcutaneous injection) are extrapolations from rodent microgram-per-kilogram studies, not validated human data. Rodent results do not automatically translate to humans, and the extrapolation has not been tested in a controlled setting. A handful of small, uncontrolled case series and self-report studies exist, but none meets the evidentiary standard that would support a defensible adverse-event profile or a reliable efficacy claim.

The US Department of Defense's Operation Supplement Safety programme has published an explicit warning that BPC-157 is "a prohibited peptide and an unapproved drug," noting that "there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans"^[3]. USADA has issued parallel guidance confirming its prohibited status for athletes^[2].

Regulatory status across our coverage area

BPC-157 has no marketing authorisation anywhere we cover. It is not a licensed medicine, not a dietary supplement, and not a food ingredient. It circulates through grey-market "research chemical" channels with a label that typically reads "not for human use" or "for research only." That label does not legalise human use and does not put the product through pharmaceutical-quality controls. See the per-country regulation pages for jurisdiction-specific detail.

The next regulatory inflection point in the US is the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23, 2026. The PCAC will review BPC-157's eligibility as a bulk drug substance for compounding under section 503A of the Food, Drug and Cosmetic Act^[4]. Whatever the committee recommends, BPC-157 is not an approved medicine today, and the PCAC advises on what compounding pharmacies may lawfully prepare rather than granting marketing authorisation.

What we do not yet know

The list of open questions is long. We do not know whether the rodent tendon, gut and central-nervous-system effects translate to humans at any dose. We do not know a human therapeutic window, because no published dose-finding work establishes one. We do not know long-term safety, especially for repeated dosing over weeks or months. We do not know how BPC-157 interacts with other medications, with pre-existing endocrine or oncologic conditions, or in pregnancy and paediatric populations.

The supply-chain picture adds a separate layer of uncertainty. Independent testing of grey-market BPC-157 vials has repeatedly flagged purity, identity and contamination failures: vials containing the wrong molecule, low-purity batches sold as 98%+, and bacterial endotoxin or microbial contamination above pharmaceutical limits. Identity testing (confirming the vial actually contains BPC-157, not just that it contains something at high purity) is rare in the grey-market supply chain.

Where this sits on PeptideMethods

BPC-157 is covered in full on our BPC-157 peptide page, which includes the mechanism of action, a timeline of key regulatory and research milestones, practical quality-check guidance for readers who already have a product, and the complete source list. If you are considering BPC-157, that conversation belongs with a clinician who knows your medical history.